Skip to main content
SpringerLink
Log in

Cost Effectiveness of Recombinant Human Insulin-Like Growth Factor I Therapy in Patients with ALS

  • Original Research Article
  • Cost Effectiveness of rhIGF-I Therapy in ALS
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Objective: Amyotrophic lateral sclerosis (ALS) is a fatal, degenerative neuromuscular disease characterised by a progressive loss of voluntary motor activity. Recombinant human insulin-like growth factor I (rhIGF-I) has been shown to be useful in treating ALS. The purpose of this study was to examine the cost effectiveness of rhIGF-I therapy in patients who have ALS.

Design: We performed a cost-effectiveness analysis from the societal perspective on 177 patients who received treatment with rhIGF-I or placebo in a North American randomised clinical trial. We estimated the incremental cost-effectiveness ratio of rhIGF-I using resource utilisation and functional status measurements from the clinical trial. Costs were estimated from 1996 US Medicare reimbursement schedules. Utility weights were elicited from ALS healthcare providers using the standard gamble technique.

Main outcome measures and results: The overall cost per quality-adjusted lifeyear (QALY) gained for rhIGF-I therapy compared with placebo was $US67 440. For the subgroups of patients who were progressing rapidly or were in earlier stages of disease at enrolment, rhIGF-I cost $US52 823 and $US43 197 per QALY gained, respectively.

Conclusions: Treatment with rhIGF-I is most cost effective in ALS patients who are either in earlier stages of the disease or progressing rapidly. The cost effectiveness of rhIGF-I therapy compares favourably with treatments for other chronic progressive diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Incidence & Prevalence (Database Online). Mountain view: timely data resources. 1997; Nov 1996

  2. Klein LM, Forshew DA. The economic impact of ALS. Neurology 1996; 47 Suppl. 2: 126S–9S

    Article  Google Scholar 

  3. Lewis ME, Neff NT, Contreras PC, et al. Insulin-like growth factor-I for treatment of motor neuronal disorders. Exp Neurol 1993; 124: 73–88

    Article  PubMed  CAS  Google Scholar 

  4. D’Ercole AJ, Ye P, Calikoglu AS, et al. The role of insulin-like growth factors in the central nervous system. Mol Neurobiol 1996; 13: 227–55

    Article  PubMed  Google Scholar 

  5. The Pink Sheet. FDC Reports 1996; June 24: T&G 2–3

  6. Lai EC, Felice KJ, Festoff BW, et al. Effect of recombinant human insulin-like growth factor I on progression of ALS: a placebo-controlled study. Neurology 1997; 49: 1621–30

    Article  PubMed  CAS  Google Scholar 

  7. Oddone EZ, Cowper P, Hamilton JD, et al. Cost effectiveness analysis of early zidovudine treatment of HIV infected patients. BMJ 1993; 307: 1322–5

    Article  PubMed  CAS  Google Scholar 

  8. Garner TI, Dardis R. Cost-effectiveness analysis of end-stage renal disease treatments. Med Care 1987; 25–34

    Google Scholar 

  9. Kattan MW, Inoue Y, Giles FJ, et al. Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia. Ann Intern Med 1996; 125: 541–8

    PubMed  CAS  Google Scholar 

  10. Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 1995; 118: 707–9

    Article  PubMed  Google Scholar 

  11. Appel V, Stewart SS, Smith G, et al. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol 1987; 22: 328–33

    Article  PubMed  CAS  Google Scholar 

  12. Bergner M, Bobbitt RA, Carter WB, et al. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19: 787–805

    Article  PubMed  CAS  Google Scholar 

  13. McGuire D, Garrison L, Armon C, et al. Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS. SSNJV/CNTF ALS Study Group. Neurology 1996; 46: 1442–4

    Article  PubMed  CAS  Google Scholar 

  14. Schulman KA, Rubenstein LE, Glick HA, et al. Relationships between sponsors and investigators in pharmacoeconomic and clinical research. Pharmacoeconomics 1995; 7: 206–20

    Article  PubMed  CAS  Google Scholar 

  15. Hillman AL, Eisenberg JM, Pauly MV, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med 1991; 324: 1362–5

    Article  PubMed  CAS  Google Scholar 

  16. Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: Gold MR, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996: 214–35

    Google Scholar 

  17. Norris FH. Care of the amyotrophic lateral sclerosis patient. In: H Mitsumoto, FH Norris, editors. Amyotrophic lateral sclerosis. A comprehensive guide to management. New York: Demos Publications, 1994: 39

  18. O’Brien BJ, Drummond MF, Labelle RJ, et al. In search of power and significance: Issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care 1994; 32: 150–63

    Article  Google Scholar 

  19. Sacristan JA, Day SJ, Navarro O, et al. JM. Use of confidence intervals and sample size calculations in health economics studies. Ann Pharmacother 1995; 29: 719–25

    PubMed  CAS  Google Scholar 

  20. Gardiner J, Hogan A, Holmes-Rovner M, et al. Confidence intervals for cost-effectiveness ratios. Med Decis Making 1995; 15: 254–63

    Article  PubMed  CAS  Google Scholar 

  21. Fenn P, McGuire A, Phillips V, et al. The analysis of censored treatment cost data in economic evaluation. Med Care 1995; 33: 851–63

    Article  PubMed  CAS  Google Scholar 

  22. Ganiats TG, Miller CJ, Kaplan RM. Comparing the quality-adjusted life-year output of two treatment arms in a randomized trial. Med Care 1995; 33: 245AS–54AS

    Google Scholar 

  23. Lee ET. Analytical estimation procedures for survival distributions. In: Statistical methods for survival data analysis. Wiley series in probability and mathematical statistics. New York: John Wiley and Sons, Inc; 1992

    Google Scholar 

  24. Glasziou PP, Simes RJ, Gelber RD. Quality adjusted survival analysis. Stat Med 1990; 9: 1259–76

    Article  PubMed  CAS  Google Scholar 

  25. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322–38

    Article  PubMed  CAS  Google Scholar 

  26. Drummond MF. Discussion: Torrance’s ‘Utility approach to measuring health-related quality of life.’ J Chron Dis 1987; 40: 601–3

    Article  Google Scholar 

  27. Patrick DL, Starks HE, Cain KC, et al. Measuring preferences for health states worse than death. Med Decis Making 1994; 14: 9–18

    Article  PubMed  CAS  Google Scholar 

  28. Torrance GW. Designing and conducting cost-utility analyses. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven Publishers, 1996

    Google Scholar 

  29. Health Care Financing Administration. 1996 Medicare program: Revisions to payment policies and adjustments to the relative value units under the physician fee schedule for calendar year 1996. Federal Register 1996

    Google Scholar 

  30. Samet JH, Libman H, Steger KA, et al. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. Am J Med 1992; 92: 495–502

    Article  PubMed  CAS  Google Scholar 

  31. Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ 1994; 3: 95–104

    Article  PubMed  CAS  Google Scholar 

  32. Mooney CZ, Duval RD. Bootstrapping: a nonparametric approach to statistical inference. Newbury Park; Sage Publications Inc. 1993

    Google Scholar 

  33. Coyle D. Statistical analysis in pharmacoeconomic studies. Pharmacoeconomics 1996; 9: 506–16

    Article  PubMed  CAS  Google Scholar 

  34. Ringle SP, Murphy JR, Alderson MK, et al. The natural history of amyotrophic lateral sclerosis. Neurology 1993; 43: 1316–22

    Article  Google Scholar 

  35. Munsat TL, Andres PL, Finison L, et al. The natural history of motoneuron loss in amyotrophic lateral sclerosis. Neurology 1988; 38: 409–13

    Article  PubMed  CAS  Google Scholar 

  36. Gubbay SS, Kahana E, Zilber N, et al. Amyotrophic lateral sclerosis. A study of its presentation and prognosis. Neurology 1985; 232: 295–300

    Article  CAS  Google Scholar 

  37. Norris F, Shepherd R, Denys E UK, et al. Onset, natural history and outcome in idiopathic adult motor neuron disease. J Neurol Sci 1993; 118: 48–55

    Article  PubMed  CAS  Google Scholar 

  38. Caroscio JT, Mulvihill MN, Sterling R, et al. Amyotrophic lateral sclerosis. It’s natural history. Neurol Clin 1987; 5: 1–8

    PubMed  CAS  Google Scholar 

  39. Rosen AD. Amyotrophic lateral sclerosis. Clinical features and prognosis. Arch Neurol 1978; 35: 638–42

    Article  PubMed  CAS  Google Scholar 

  40. Welch HG, Larson EB. Cost-effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. N Engl J Med 1989; 321: 807–12

    Article  PubMed  CAS  Google Scholar 

  41. Evans RW. Cost-effectiveness analysis of transplantation. Surg Clin North Am 1986; 66: 603–16

    PubMed  CAS  Google Scholar 

  42. US Bureau of the Census. Statistical abstract of the United States 1997. 117th ed. Washington, DC: US Bureau of the Census, 1997

  43. Torrance GW. Utility approach to measuring health-related quality of life. J Chron Dis 1987; 40: 593–600

    Article  PubMed  CAS  Google Scholar 

  44. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146: 473–81

    CAS  Google Scholar 

  45. Gold MR, Patrick DL, Torrance GW, et al. Identifying and valuing outcomes. In: Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996: 82–123

    Google Scholar 

  46. McDonald ER. Psychosocial-spiritual overview. In: H Mitsumoto, FH Norris, editors. Amyotrophic lateral sclerosis: a comprehensive guide to management. New York: Demos Publications, 1994: 206–22

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Covance Health Economics and Outcomes Services Inc., 1100 New York Ave, NW, Suite 200 East, Washington, DC, 20005-3934, USA

    Stacey J. Ackerman (Principal), Erin M. Sullivan & Kathleen M. Beusterien

  2. Allegheny University, Hahnemann Hospital, ALS Clinical Services Center, Philadelphia, Pennsylvania, USA

    Howard M. Natter

  3. Forbes Norris MDA/ALS Center, San Francisco, California, USA

    Deborah F. Gelinas

  4. University of Washington, Seattle, Washington, USA

    Donald L. Patrick

Authors
  1. Stacey J. Ackerman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erin M. Sullivan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kathleen M. Beusterien
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Howard M. Natter
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Deborah F. Gelinas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Donald L. Patrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stacey J. Ackerman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ackerman, S.J., Sullivan, E.M., Beusterien, K.M. et al. Cost Effectiveness of Recombinant Human Insulin-Like Growth Factor I Therapy in Patients with ALS. Pharmacoeconomics 15, 179–195 (1999). https://doi.org/10.2165/00019053-199915020-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199915020-00006

Keywords

Search

Navigation